Dako to develop companion diagnostic for Pfizer and Merck KGaA's joint cancer candidate

Pharma bigwigs Merck KGaA and Pfizer ($PFE) announced they are collaborating with Dako to develop a companion diagnostic to accompany their investigational immune checkpoint inhibiting candidate in the fight against cancer.

The trio will work to design a companion diagnostic to assess programmed death-ligand 1 (PD-L1) protein expression levels in tumor tissue as well as its microenvironment, which includes tumor-associated immune cells, the companies said in a release...